21 / 26
Page 48
Notes:
allied
academies
J Pharmacol Ther Res 2017 Volume 1 Issue 2
November 02-03, 2017 Chicago, USA
4
th
International Congress on
International Conference and Exhibition on
Drug Discovery, Designing and Development
Biochemistry, Molecular Biology: R&D
&
Modified glycol chitosan nanocarriers carry hydrophobic materials into tumours
Akhtar Aman
Shaheed Benazir Bhutto University, Pakistan
D
evelopment of efficient delivery system for hydrophobic
drugs remains a major concern in chemotherapy. The
objective of the current study is to develop polymeric drug-
delivery system for etoposide from amphiphilic derivatives of
glycol chitosan, capable to improve thepharmacokinetics and to
reduce the adverse effects of etoposide due to various organic
solvents used in commercial formulations for solubilization
of etoposide. As a promising carrier, amphiphilic derivatives
of glycol chitosan were synthesized by chemical grafting of
palmitic acid N-hydroxysuccinimide and quaternization to
glycol chitosan backbone. To this end, a 7.9 kDa glycol chitosan
was modified by palmitoylation and quaternisation into 13 kDa.
Nano sizedmicelles prepared fromthis amphiphilic polymerhad
the capability to encapsulate up to 3 mg/ml etoposide. The
pharmacokinetic results indicated that GCPQ based etoposide
formulation transformed the biodistribution pattern. AUC 0.5-
24 hr showed statistically significant difference in ETP-GCPQ vs.
commercial preparation in liver (25 vs 70, p<0.001), spleen (27
vs. 36, P<0.05), lungs (42 vs. 136, p<0.001), kidneys (25 vs. 30,
p<0.05) and brain (19 vs. 9, p<0.001). Using the hydrophobic
fluorescent dyeNile red, we showed that micelles efficiently
delivered their payload to MCF7 and A2780 cancer cells in-
vitro and to A431 xenografttumor
in-vivo
, suggesting these
systems could deliver hydrophobic anti-cancer drugs such as
etoposide to tumors. The pharmacokinetic results indicated
that the GCPQmicelles transformed the biodistribution pattern
and increased etoposide concentration in the brain significantly
compared to free drug after intravenous administration. GCPQ
based formulations not only reducedside effects associated
with current available formulations but also increased their
transport through the biological barriers, thus making it a good
delivery system.
Speaker Biography
Akhtar Aman has completed his PhD from Peshawar University under Hec Scholarship.
During his PhD studies, he also worked as Visiting Scientist at Center for Cancer
Medicine, School of Pharmacy, University College London, UK. He is currently serving as
Assistant Professor of Pharmaceutics at Shaheed Benazir Bhutto University, Sheringal,
Pakistan. He has published more than 10 papers in reputed journals
e:
dramanrph@sbbu.edu.pk